A kidney drug kept working kidneys working — no one on it reached kidney failure in the trial

For people with IgA nephropathy, a kidney disease that can slowly lead to failure and dialysis, time matters. Vor Bio reported that its drug telitacicept largely preserved kidney function over two years in a late-stage study, cutting the risk of a confirmed 30% decline in kidney function by 89% compared with placebo. No patient on the drug reached the study's kidney-failure endpoint, compared with five on placebo, including two who needed dialysis.

SDG 3 · Good health and well-being — Mechanism: tech innovation